Skip to main content
    M

    Marker Therapeutics Inc (MRKR)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.83
    -0.04 (-4.76%)

    Market Cap: $14.51M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Marker Therapeutics Inc (MRKR) Financials: Revenue, Profit and Cash Flow

    Updated Nov 12, 2026. Financial statements from company filings, amounts in US dollars.

    Marker Therapeutics reported revenue of $3.55M for the fiscal year ended Dec 31, 2025, down 46.2% from the year before. That year, net income was -$12.16M with a net margin of -343.0%, operating cash flow was -$12.01M and free cash flow was -$12.01M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of -$1.84M.

    Revenue and Margins

    Over the 8 years to Dec 2025, revenue grew from $183.06K, a compound annual rate of 44.9%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$3.55M-46.2%100.0%-363.5%-343.0%
    Dec 2024$6.59M+99.1%100.0%-168.7%-162.8%
    Dec 2023$3.31M-5.8%100.0%-440.4%-248.8%
    Dec 2022$3.51M+183.0%100.0%-563.3%-851.9%
    Dec 2021$1.24M+166.0%100.0%-3179.3%-3372.7%
    Dec 2020$466.79K+118.9%100.0%-6188.2%-6149.7%
    Dec 2019$213.19K+3.5%100.0%-10567.3%-10050.9%
    Dec 2018$205.99K+12.5%-60095.0%-71930.3%-71826.4%
    Dec 2017$183.06KN/A100.0%-6271.1%-5999.1%
    Dec 2016$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$3.55M$6.59M$3.31M$3.51M$1.24M$466.79K$213.19K$205.99K$183.06K$0
    Cost of revenue$0$0$0$0$0$0$0$124.00M$0$0
    Gross profit$3.55M$6.59M$3.31M$3.51M$1.24M$466.79K$213.19K-$123.79M$183.06K$0
    Research and development$11.80M$13.47M$10.42M$11.97M$27.79M$18.88M$12.76M$124.00M$5.25M$0
    Operating income-$12.89M-$11.12M-$14.58M-$19.79M-$39.48M-$28.89M-$22.53M-$148.17M-$11.48M$0
    Net income-$12.16M-$10.73M-$8.24M-$29.93M-$41.88M-$28.71M-$21.43M-$147.96M-$10.98M$0
    EBITDA-$12.77M-$11.12M-$14.58MN/A-$38.72M-$27.78M-$22.22M-$147.97M-$11.47M$0
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$0$0$0$1.10M$0$0$0$2.25M$1.93M$1.17M$1.24M$1.06M
    Gross profit$0$0$0$1.10M$0$0$0$2.25M$1.93M$1.17M$1.24M$1.06M
    Operating income-$3.23M-$2.62M-$4.07M-$1.88M-$3.37M-$5.12M-$4.96M-$3.86M-$2.40M-$2.31M-$2.55M-$2.94M
    Net income-$1.84M-$1.83M-$3.18M-$1.70M-$2.00M-$4.02M-$4.45M-$3.84M-$2.31M-$2.19M-$2.39M-$2.80M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents of $16.07M were 84.3% of total assets of $19.07M, against total liabilities of $2.27M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$19.07M$22.02M$17.13M$34.42M$68.14M$45.61M$46.36M$62.14M$5.18M$7.92M
    Current assets$19.07M$22.02M$17.13M$16.62M$45.98M$24.41M$45.49M$62.00M$5.18M$7.92M
    Cash and equivalents$16.07M$19.19M$15.11M$11.78M$42.35M$21.35M$43.90M$61.75M$5.13M$7.85M
    Total liabilities$2.27M$3.46M$3.07M$14.82M$24.15M$18.27M$2.27M$2.80M$1.52M$1.74M
    Short-term debtN/AN/AN/A$577.20K$620.49K$388.79K$204.13K$49.00K$5.00K$5.00K
    Shareholder equity$16.80M$18.56M$14.05M$19.60M$43.99M$27.34M$44.09M$59.34M$3.66M$6.18M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$12.50M$14.59M$17.43M$19.07M$21.73M$14.77M$16.99M$22.02M$10.91M$11.68M$14.09M$17.13M
    Total liabilities$2.00M$2.42M$3.64M$2.27M$3.35M$4.28M$2.50M$3.46M$3.46M$1.97M$2.30M$3.07M
    Cash and equivalents$9.04M$11.33M$14.92M$16.07M$17.59M$10.46M$13.69M$19.19M$9.00M$7.80M$11.32M$15.11M
    Shareholder equity$10.50M$12.17M$13.80M$16.80M$18.39M$10.49M$14.49M$18.56M$7.45M$9.70M$11.79M$14.05M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$12.01M-$10.91M-$16.44M-$26.97M-$27.28M-$20.03M-$18.28M-$14.48M-$8.44M-$6.51M
    Capital expenditures$1$4$1$3$1.57M$3.42M$374.98K$147.67K$0$147.67K
    Free cash flow-$12.01M-$10.91M-$16.44M-$26.97M-$28.85M-$23.46M-$18.66M-$14.63M-$8.44M-$6.66M
    Share repurchasesN/AN/AN/AN/AN/AN/AN/AN/A$310.49K$0
    Investing cash flow$0$0$18.66M-$4.95M-$3.13M-$9.25M-$374.98K-$147.67K$0$0
    Financing cash flow$9.86M$14.99M$1.11M$202.13K$52.56M$6.74M$816.48K$71.25M$5.72M$7.78M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$2.49M-$3.72M-$1.40M-$1.90M-$2.74M-$1.88M-$5.50M-$4.70M$1.20M-$3.57M-$3.84M-$2.37M
    Capital expendituresN/AN/A$2$4$4$2$3$5$1$0$2$4
    Free cash flowN/AN/A-$1.40M-$1.90M-$2.74M-$1.88M-$5.50M-$4.70M$1.20M-$3.57M-$3.84M-$2.37M
    Last 12 quarters

    Frequently Asked Questions About MRKR

    What is Marker Therapeutics' annual revenue?

    Marker Therapeutics reported revenue of $3.55M for the fiscal year ended Dec 31, 2025.

    How fast is Marker Therapeutics' revenue growing?

    Revenue was down 46.2% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 0.3%.

    Is Marker Therapeutics profitable?

    No. Marker Therapeutics reported net income of -$12.16M for the fiscal year ended Dec 31, 2025, with a net margin of -343.0%.

    How much free cash flow does MRKR generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$12.01M minus capital expenditures of $1 produced free cash flow of -$12.01M.

    How much debt does Marker Therapeutics have?

    The balance sheet dated Dec 31, 2025 reported cash and equivalents of $16.07M.